Cargando…
Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma
Background: Combination therapy with anti-programmed death-ligand 1 monoclonal antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab (Atezo/Bev) was approved in 2020 as a first-line treatment for unresectable hepatocellular carcinoma (HCC). Atezo/Bev therapy is relativ...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534657/ https://www.ncbi.nlm.nih.gov/pubmed/34677270 http://dx.doi.org/10.3390/curroncol28050352 |
_version_ | 1784587604348370944 |
---|---|
author | Eso, Yuji Takeda, Haruhiko Taura, Kojiro Takai, Atsushi Takahashi, Ken Seno, Hiroshi |
author_facet | Eso, Yuji Takeda, Haruhiko Taura, Kojiro Takai, Atsushi Takahashi, Ken Seno, Hiroshi |
author_sort | Eso, Yuji |
collection | PubMed |
description | Background: Combination therapy with anti-programmed death-ligand 1 monoclonal antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab (Atezo/Bev) was approved in 2020 as a first-line treatment for unresectable hepatocellular carcinoma (HCC). Atezo/Bev therapy is relatively well tolerated; however, factors that can predict its response have not yet been reported. Thus, we aimed to investigate whether the pretreatment neutrophil-to-lymphocyte ratio (NLR) could predict the therapeutic response in patients with HCC treated with Atezo/Bev therapy. Methods: We analyzed the course of 40 patients with HCC who received Atezo/Bev therapy at our hospital and attempted to identify pretreatment factors that could predict response by comparing those who achieved disease control with those who did not. Results: The pretreatment NLR value in patients who achieved disease control was significantly lower than that in patients with disease progression (2.47 vs. 4.48, p = 0.013). Using the optimal NLR cut-off value for predicting response (3.21) determined by receiver operating characteristic curve analysis, patients with NLR ≤ 3.21 had significantly better progression-free survival than those with NLR > 3.21 (p < 0.0001), although there were no significant differences in liver function or tumor-related background factors between the two groups. Conclusions: The pretreatment NLR value may be a useful predictor of response to Atezo/Bev therapy for HCC. |
format | Online Article Text |
id | pubmed-8534657 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85346572021-10-23 Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma Eso, Yuji Takeda, Haruhiko Taura, Kojiro Takai, Atsushi Takahashi, Ken Seno, Hiroshi Curr Oncol Article Background: Combination therapy with anti-programmed death-ligand 1 monoclonal antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab (Atezo/Bev) was approved in 2020 as a first-line treatment for unresectable hepatocellular carcinoma (HCC). Atezo/Bev therapy is relatively well tolerated; however, factors that can predict its response have not yet been reported. Thus, we aimed to investigate whether the pretreatment neutrophil-to-lymphocyte ratio (NLR) could predict the therapeutic response in patients with HCC treated with Atezo/Bev therapy. Methods: We analyzed the course of 40 patients with HCC who received Atezo/Bev therapy at our hospital and attempted to identify pretreatment factors that could predict response by comparing those who achieved disease control with those who did not. Results: The pretreatment NLR value in patients who achieved disease control was significantly lower than that in patients with disease progression (2.47 vs. 4.48, p = 0.013). Using the optimal NLR cut-off value for predicting response (3.21) determined by receiver operating characteristic curve analysis, patients with NLR ≤ 3.21 had significantly better progression-free survival than those with NLR > 3.21 (p < 0.0001), although there were no significant differences in liver function or tumor-related background factors between the two groups. Conclusions: The pretreatment NLR value may be a useful predictor of response to Atezo/Bev therapy for HCC. MDPI 2021-10-14 /pmc/articles/PMC8534657/ /pubmed/34677270 http://dx.doi.org/10.3390/curroncol28050352 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Eso, Yuji Takeda, Haruhiko Taura, Kojiro Takai, Atsushi Takahashi, Ken Seno, Hiroshi Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma |
title | Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma |
title_full | Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma |
title_fullStr | Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma |
title_full_unstemmed | Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma |
title_short | Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma |
title_sort | pretreatment neutrophil-to-lymphocyte ratio as a predictive marker of response to atezolizumab plus bevacizumab for hepatocellular carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534657/ https://www.ncbi.nlm.nih.gov/pubmed/34677270 http://dx.doi.org/10.3390/curroncol28050352 |
work_keys_str_mv | AT esoyuji pretreatmentneutrophiltolymphocyteratioasapredictivemarkerofresponsetoatezolizumabplusbevacizumabforhepatocellularcarcinoma AT takedaharuhiko pretreatmentneutrophiltolymphocyteratioasapredictivemarkerofresponsetoatezolizumabplusbevacizumabforhepatocellularcarcinoma AT taurakojiro pretreatmentneutrophiltolymphocyteratioasapredictivemarkerofresponsetoatezolizumabplusbevacizumabforhepatocellularcarcinoma AT takaiatsushi pretreatmentneutrophiltolymphocyteratioasapredictivemarkerofresponsetoatezolizumabplusbevacizumabforhepatocellularcarcinoma AT takahashiken pretreatmentneutrophiltolymphocyteratioasapredictivemarkerofresponsetoatezolizumabplusbevacizumabforhepatocellularcarcinoma AT senohiroshi pretreatmentneutrophiltolymphocyteratioasapredictivemarkerofresponsetoatezolizumabplusbevacizumabforhepatocellularcarcinoma |